About the Webinar
3D epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to overcome therapy resistance remains largely unaddressed. In this webinar, learn how researchers at the Garvan Institute used 3D genomics to explore mechanisms by which an FDA-approved epigenetic therapy can suppress tumor growth in ER+ breast cancer.
- Learn about 3D epigenome remodeling as an essential mechanism of gene deregulation in breast cancer.
- Understand the mechanisms by which Decitabine-induced DNA hypomethylation can suppress tumor growth in preclinical metastatic ER+ breast tumor xenograft models.
- Explore the potential of using epigenetic therapy to target ER+ endocrine-resistant breast cancer via DNA methylation-dependent rewiring of 3D chromatin interactions.
Meet the Speakers
Joanna Achinger-Kawecka, PhDGroup Leader, Garvan Institute of Medical Research
Dr. Achinger-Kawecka is a Group Leader of the 3D Epigenome in Cancer group at the Garvan Institute of Medical Research. Joanna completed her PhD at the University of Tübingen in Germany. The primary objective of her research team is to gain insight into the role of 3D genome organization in the development of treatment-resistant breast and prostate cancer. The group aims to identify new therapeutic targets and biomarkers to improve the treatment of metastatic disease.
Kristin Sikkink, PhDDirector of Research, Arima Genomics
Kristin is our newly appointed Director of Research and holds a PhD in Biology. She leads and manages Arima's clinical and discovery research programs.